Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
- 20 August 2003
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 56 (6), 600-612
- https://doi.org/10.1046/j.1365-2125.2003.01893.x
Abstract
Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.Keywords
This publication has 77 references indexed in Scilit:
- Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane β-agonistsJournal of Allergy and Clinical Immunology, 1999
- Review of therapeutically equivalent alternatives to short acting beta 2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalersThorax, 1999
- Importance of drug-device interaction in determining systemic effects of inhaled cor ticosteroidsThe Lancet, 1999
- Liposomal Drug FormulationsDrugs, 1998
- Selecting and using nebuliser equipmentThorax, 1997
- Liposomal DNA vectors for cystic fibrosis gene therapy. Current applications, limitations, and future directionsAdvanced Drug Delivery Reviews, 1996
- Pulmonary Delivery of Liposome-Encapsulated Drugs in Asthma TherapyClinical Immunotherapeutics, 1995
- Nebulizer Performance: AFLM StudyRespiration, 1995
- Bioequivalence of metered-dose inhaled medicationsJournal of Allergy and Clinical Immunology, 1993
- Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.Thorax, 1988